InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
NEW YORK & HERZLIYA, Israel, June 22, 2026 (GLOBE NEWSWIRE) — InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (dba Canndoc) (“InterCure” or the “Company”), today announced that, further to the Company’s prior reports regarding growing demand in Germany and opport…
The funding includes investments commitments from key shareholders of the Company, including the Companys CEO Alexander Rabinovich, as well as leading pharma-focused…
Subscribe to our NewsletterBe the first to receive the latest buzz contests & more! |